'Rare out­lier­s': Feng Zhang eyes a new path to ge­net­ic med­i­cine de­liv­ery with ex-Al­ny­lam lead­ers and $193M

Mar­quee CRISPR sci­en­tist Feng Zhang, two-decade Al­ny­lam on­col­o­gy head Akin Ak­inc and sea­soned biotech gu­ru John Maraganore have come to­geth­er for a new bet on gene edit­ing, aim­ing to go be­yond the scope of the ex­ist­ing crop of clin­i­cal-stage tools.

They hope to de­liv­er big time — at­tempt­ing to up­end where po­ten­tial ther­a­peu­tic gold mines can go in the body, how they get shut­tled and the types of dis­eases the long-hyped ge­net­ic med­i­cine field can treat.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER